Key result
Standard-dose enoxaparin in morbidly obese patients yields supratherapeutic anti-Xa levels in ~51%.
Why the study?
The study aimed to characterize steady-state antifactor Xa peak levels and assess bleeding complications in morbidly obese patients receiving standard treatment doses of enoxaparin.
Cohort (n=99)
No
Standard treatment dosing of enoxaparin in morbidly obese patients frequently results in supratherapeutic antifactor Xa levels, suggesting a need for routine monitoring.
Answers are grounded in this paper and cite their sources.
Variable anti-Xa levels seen in morbidly obese patients on enoxaparin; hypothesis-generating and should not yet change practice.
Study Objectives To characterize antifactor Xa peak levels (as therapeutic, subtherapeutic, and supratherapeutic) in morbidly obese patients receiving treatment doses of enoxaparin, using a therapeutic range of 0.5–1.1 units/ml, and to assess the occurrence of bleeding complications in these patients. Design Retrospective cohort study. Setting Community hospital. Patients Ninety‐nine morbidly obese patients (body mass index [BMI] higher than 40 kg/m2 or total body weight more than 150 kg) who received at least three doses of the standard treatment dosage of enoxaparin and had steady‐state antifactor Xa peak levels between April 2009 and January 2014. Measurements and Main Results Data were collected from patients' medical records on age, sex, height, weight, BMI, serum creatinine concentration, creatinine clearance (using lean body weight as well as adjusted body weight), antifactor Xa level, and time of blood collection for measurement of antifactor Xa level. Enoxaparin therapy was monitored by using antifactor Xa levels; steady‐state enoxaparin antifactor Xa levels were measured 4 hours after administration of the third dose for peak level monitoring. The primary outcome was the proportion of patients whose steady‐state antifactor Xa peak values were in the therapeutic (0.5–1.1 units/ml), subtherapeutic, and supratherapeutic ranges. The secondary outcome was occurrence of major bleeding. Univariate regression analysis was performed to identify the correlation between baseline patient characteristics and antifactor Xa levels. Most of the patients (50 [50.5%]) had supratherapeutic levels, 35 (35.4%) had levels within the therapeutic peak range (0.5–1.1 units/ml), and 14 (14.1%) had subtherapeutic levels. No bleeding was observed in any of the 99 patients. Univariate analysis revealed a negative association between antifactor Xa levels and serum creatinine concentration (r = −0.262, p=0.009). Conclusion Based on the results of this study, monitoring antifactor Xa levels is warranted to ensure the safety and efficacy of enoxaparin in the obese patient population (defined as a total body weight more than 150 kg or BMI higher than 40 kg/m2). Enoxaparin dose individualization and antifactor Xa level monitoring need further validation with clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2015) conducted a cohort in Morbid obesity requiring treatment-dose enoxaparin (n=99). Standard treatment dosage of enoxaparin monitored with antifactor Xa levels was evaluated on Proportion of patients with steady-state antifactor Xa peak values in the therapeutic (0.5-1.1 units/ml), subtherapeutic, and supratherapeutic ranges. Standard treatment-dose enoxaparin in morbidly obese patients resulted in supratherapeutic antifactor Xa levels in 50.5%, therapeutic levels in 35.4%, and subtherapeutic levels in 14.1%.
Synapse has enriched 10 related papers. Consider them for comparative context: